Clinical trialsCompany release

ProMIS flags Q1 2027 topline data for Alzheimer's antibody PMN310 in Phase 1b

🇺🇸 ProMIS Neurosciences Inc. (PMN) · Thu 12 Nov 2026

The clinical-stage biotech says PRECISE-AD results are due in the first quarter of 2027, with cash expected to last through 2027.

ProMIS Neurosciences has published a corporate slide deck on PMN310, its lead antibody for early Alzheimer's disease, stating that topline data from the Phase 1b PRECISE-AD trial are expected in the first quarter of 2027.

The company describes PMN310 as targeting toxic amyloid-beta oligomers. The deck also says its cash runway extends through 2027, which would cover the planned data readout.

The presentation cites blinded interim data as of 22 July 2026. Because those figures are blinded, they do not show how PMN310 performs against a comparator, and the summary of the deck gives no detail on their content.

ProMIS also positions PMN310 against the risk of amyloid-related imaging abnormalities (ARIA), which carry boxed warnings on the labels of Leqembi and Kisunla. As general context, a boxed warning is the most prominent safety warning on a US product label. How PMN310 compares on ARIA will have to be shown by trial data, which the deck presents as forthcoming.

What it means for your team

  • Regulatory and clinical teams tracking the amyloid-targeting field should note the Q1 2027 topline date for PRECISE-AD as a potential data milestone.
  • Pharmacovigilance teams should expect any ARIA comparison with Leqembi and Kisunla to be judged on unblinded safety data, not on the blinded interim figures in the deck.
  • Market-access analysts should note that the company's stated cash runway through 2027 covers the planned readout, but the deck does not describe later-stage plans.

Company's press release (SEC filing): ProMIS Neurosciences Inc. ↗

Article written by VigiEye from the official source (ProMIS Neurosciences Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →